FDA warned EvoLife Wellness that its website wrongly calls compounded semaglutide and tirzepatide "FDA-Approved," making the drugs misbranded.
What happened
FDA reviewed the company's website, evolifewellness.com, in August 2025 and found it offers compounded semaglutide and tirzepatide drug products. The site claimed these products were "FDA-Approved" and "Clinically Proven," even though compounded drugs are not FDA-approved. FDA says those claims are false or misleading, so the products are misbranded and shipping them across state lines is a prohibited act.
What FDA found
The website called the compounded drugs "FDA-Approved" when compounded drugs are not FDA-approved, so the labeling is false or misleading.
FDCA section 502(a) [21 U.S.C. § 352(a)]Advertising for a compounded drug that is false or misleading in any way misbrands that drug.
FDCA section 502(bb) [21 U.S.C. § 352(bb)]The company introduced or delivered these misbranded drugs into interstate commerce, which is a prohibited act.
FDCA section 301(a) [21 U.S.C. § 331(a)]Receiving misbranded drugs in interstate commerce, or delivering them, is also a prohibited act.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
FDA tells the company to immediately stop using the misleading "FDA-Approved" language and, within 15 working days, send a written response to CDER's Office of Compounding Quality and Compliance describing the steps taken, how repeat violations will be prevented, and supporting documents.
Who should pay attention
- telehealth companies and online pharmacies selling compounded semaglutide or tirzepatide
- compounding pharmacies whose products are marketed by partner clinics
- marketing and compliance staff who write website copy for drug products
This is a summary. Read the original letter on fda.gov.